(Press-News.org) Research: New research has revealed how the Emperor Penguin is able to dive to depths of over 500m and stay under water for up to 27 minutes – deeper and longer than any of its fellow avian species.
Researchers from the University of California will be presenting their new findings at the International Penguin Conference (IPC) which begins in Bristol today [02 September].
It's the first time the conference has been held in Europe, with 200 delegates from 30 countries sharing their latest research and knowledge at the University of Bristol and Bristol Zoo Gardens between 2 and 6 September.
Alexandra Wright and Dr Paul Ponganis investigated the heart rate response of Emperor Penguins as they made foraging trips to see from the Cape Washington Colony in Antarctica.
They measured heart rates using an electrocardiogram (ECG) recorder and looked at dive behaviour with a time depth recorder (TDR) and found that the penguins slow their heart from the normal rate of around 70 beats per minute to as low as 10 beats per minute.
Emperor Penguins also have unusually structured hemoglobin to allow it to function at low oxygen levels, solid bones to reduce barotrauma - physical damage to body tissues caused by a difference in pressure between a gas space inside, or in contact with the body, and the surrounding fluid, and the ability to reduce metabolism and to shut down non-essential organ functions.
The profound decline in heart rate - known as bradycardia – decreases oxygen consumption, conserves the respiratory and blood oxygen stores, and isolates muscle, which must rely instead on its own oxygen store which is bound to the muscle protein, myoglobin.
Although this heart rate response contrasts with other birds and terrestrial mammals, it is similar to the dive response of marine mammals.
INFORMATION:
Britain is to host the International Penguin Conference from 2 to 6 September in Bristol.
It's the first time the conference has been held in Europe, with 200 delegates from 30 countries sharing their latest research and knowledge.
Archbishop Desmond Tutu has recorded a special video message to launch the event.
With five penguin species listed as endangered and a further six as vulnerable, work to ensure the survival of penguins in the wild has never been more important.
Among the wealth of new research which will be presented at the conference, the University of California will reveal just how Emperor Penguins are able to dive to depths of over 500m and stay under water for up to 27 minutes.
Delegates will also get a chance to sample papers on everything from "monitoring global penguin population change" to "the power of poo".
PHOTO
Available to download from here: https://fluff.bris.ac.uk/fluff/u2/inpaw/fdcfWiTllMpDQ3Sst8TvAgHFD/.
Caption: Diving Emperor Penguins during a foraging trip from the Cape Washington colony in Antarctica.
Credit: Paul Ponganis, University of California.
Please note: this photo is for single use only to illustrate this press release and is not to be archived. Please credit the copyright holder Paul Ponganis, University of California, in each case.
More photos of the Emperor Penguins at the Cape Washington colony are available to download here: https://fluff.bris.ac.uk/fluff/u1/inpaw/5jJPq81odoHZW_xYuAfzmAHQC/
Notes to editors
More information on the 8th International Penguin Conference being held in Bristol is available from http://www.penguinconference.org
A further press release about the conference is available here: http://www.bristol.ac.uk/news/2013/9686.html
For further information please contact Philippa Walker in the Press Office, University of Bristol, tel 0117 928 7777, email philippa.walker@bristol.ac.uk
World-leading penguin experts come to Britain
2013-09-02
ELSE PRESS RELEASES FROM THIS DATE:
Droplet Digital PCR enables reproducible quantification of microRNA biomarkers
2013-09-02
Seattle, Wash. — September 1, 2013 — A study published online in Nature Methods today demonstrated that Droplet Digital PCR (ddPCR™) technology can be used to precisely and reproducibly quantify microRNA (miRNA) in plasma and serum across different days, paving the way for further development of miRNA and other nucleic acids as circulating biomarkers.
"In the field of circulating microRNA diagnostics, droplet digital PCR enables us to finally perform biomarker studies in which the measurements are directly comparable across days within a laboratory and even among different ...
Stanford scientists show how antibiotics enable pathogenic gut infections
2013-09-02
STANFORD, Calif. — A new study by researchers at the Stanford University School of Medicine could help pinpoint ways to counter the effects of the antibiotics-driven depletion of friendly, gut-dwelling bacteria.
A number of intestinal pathogens can cause problems after antibiotic administration, said Justin Sonnenburg, PhD, assistant professor of microbiology and immunology and the senior author of the study, to be published online Sept. 1 in Nature. Graduate students Katharine Ng and Jessica Ferreyra shared lead authorship.
"Antibiotics open the door for these pathogens ...
Scientists sequence genome of high-value grape, seek secrets of wine's aroma
2013-09-02
Demystifying the chemical processes that create a wine's aroma, and the invaluable potential application of that understanding in winemaking, is the new objective of scientists in Uruguay who, with European partners, also recently sequenced the genome of the high-value Tannat grape, from which "the most healthy of red wines" are fermented.
Meanwhile, a quick, $1 test in development by researchers in Paraguay and Uruguay promises to reduce the economic and health burden of 3 million cases of syphilis in Latin America -- a disease readily treated and cured if diagnosed ...
Drug reduces hospitalizations and cost of treating young children with sickle cell anemia
2013-09-02
A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.
The study is the largest ever focusing on the economic impact of the drug hydroxyurea in children with the inherited blood disorder. The result supports expanded use of the drug to extend the length and quality of life for ...
Risk factors for cardiovascular problems found to be inverse to disease and deaths
2013-09-02
Hamilton, ON (September 2, 2013) – Despite living with the highest risk factors for heart disease, people in high income countries suffer less from serious cardiovascular disease, says an international study by the global PURE (Prospective Urban Rural Epidemiology ) collaboration and led by McMaster University researchers.
At the same time, the study found that people in low income countries, although living with fewer risk factors for heart disease, have a higher incidence of serious cardiovascular disease including death.
"These findings were a total surprise," ...
Metabolically healthy women have same CVD risk regardless of BMI
2013-09-02
Amsterdam, The Netherlands – Monday 2 September 2013: Metabolically healthy women have the same cardiovascular disease risk regardless of their BMI, according to research presented at the ESC Congress today by Dr Søren Skøtt Andersen and Dr Michelle Schmiegelow from Denmark. The findings in more than 260,000 subjects suggest that obese women have a window of opportunity to lose weight and avoid developing a metabolic disorder, which would increase their CVD risk.
Dr Schmiegelow said: "Obesity and/or metabolic disorders (hypertensive disorders [hypertension, gestational ...
Pacemaker for slow heart rhythm restores life expectancy
2013-09-02
Amsterdam, The Netherlands – Monday 2 September 2013 : Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients.
Dr Udo said: "Previous studies describing the survival of pacemaker patients used data that is more than 20 years old and cannot be used anymore for patient counselling and benchmarking. There have been considerable changes in pacemaker technology ...
ASSURE study of experimental agent to raise HDL yields 'disappointing and surprising' results
2013-09-02
AMSTERDAM, The Netherlands, 2 September2013 – The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.
The lack of efficacy of RVX-208 is "disappointing and surprising, given promising earlier findings," noted lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research ...
Common blood pressure drug reduces aortic enlargement in Marfan syndrome
2013-09-02
AMSTERDAM, The Netherlands - A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome.
Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment.
"Our study is the first large, prospective randomized study to assess the effects ...
Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS
2013-09-02
AMSTERDAM, The Netherlands – Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress.
"Compared with placebo, treatment with alogliptin resulted in similar rates of the primary endpoint, which was a composite of cardiovascular death, myocardial ...